Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056650 | 1.00 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL6056645 | 1.00 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL6449388 | 0.92 | ACHE (0.33) | — | |
| SCHEMBL6449386 | 0.92 | ACHE (0.33) | — | |
| SCHEMBL6449390 | 0.92 | ACHE (0.33) | — | |
| SCHEMBL6447969 | 0.89 | ESR1 (0.45) | ESR1ESR2 | |
| SCHEMBL6056809 | 0.89 | ESR1 (0.45) | ESR1ESR2 | |
| SCHEMBL6447971 | 0.89 | ESR1 (0.45) | ESR1ESR2 | |
| SCHEMBL6449784 | 0.86 | CA1 (0.33) | ESR1ESR2 | |
| SCHEMBL6449774 | 0.86 | CA1 (0.33) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453913-A4 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | HUANG LIREN (US) | 2005-07-07 | — | — | US | disclosed |
| EP-1453913-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | Antex Pharma, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003062443-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | ALK, CYP11B2, ALKBH2 | ESR1 1005/4885ESR2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.